Compositions and methods for delivering GDNF to skeletal muscles to result
in a therapeutic effect are disclosed. The compositions and methods use
adeno-associated virus (AAV)-based gene delivery systems. The methods are
useful for treating motoneuron diseases, such as amyotrophic lateral
sclerosis (ALS).